A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
J Viral Hepat
; 22(12): 1011-9, 2015 Dec.
Article
in En
| MEDLINE
| ID: mdl-26183611
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Carbamates
/
Viral Nonstructural Proteins
/
Hepacivirus
/
Hepatitis C, Chronic
/
Heterocyclic Compounds, 4 or More Rings
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Viral Hepat
Journal subject:
GASTROENTEROLOGIA
Year:
2015
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom